Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 2403 • ACR Convergence 2025
Differential Risk of Inpatient Admissions Among SLE Subgroups: A Population-Based Analysis
Jaime Flores-Gouyonnet¹, Erika Navarro-Mendoza¹, Mario Bautista-Vargas¹, Ali Ardekani¹, Maria Cuellar-Gutierrez¹, Gabriel Figueroa-Parra², Mariana Gonzalez-Treviño³, Alain Sanchez-Rodriguez⁴, Andrew C. Hanson¹, Cassondra Hulshizer⁵, Cynthia Crowson⁶ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Vanderbilt University Medical Center, Nashville, TN, ⁴ABC Medical Center, Ciudad de México, Federal District, Mexico, ⁵Mayo Clinic, Rochester, ⁶Mayo Clinic, Stewartvillle, MN
Background/Purpose: SLE is clinically heterogeneous and associated with increased hospitalizations. However, it remains unclear which patient subgroups drive this excess in unplanned healthcare use. We…
Abstract Number: 0855 • ACR Convergence 2025
Certolizumab Pegol to Prevent Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome and Lupus Anticoagulant (IMPACT): Results from Ongoing Recruitment of a Prospective, Single-Arm, Open-Label, Phase 2 Trial
Jane Salmon¹, Mimi Kim², Marta Guerra¹, Joseph Worden³, Carl Laskin⁴, Maria DeSancho⁵, Inna Landres⁵, Jason S. Knight⁶, Haley Slosberg¹, Margaret Minett¹ and Ware Branch⁷, ¹Hospital for Special Surgery, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³University of Utah School of Medicine, Salt Lake City, ⁴University of Toronto, Toronto, ON, Canada, ⁵Weill Cornell Medicine, New York, ⁶University of Michigan, Ann Arbor, MI, ⁷University of Utah Health Sciences Center, Salt Lake City, UT
Background/Purpose: The IMPACT trial (NCT03152058) showed that certolizumab appears effective in preventing placenta-mediated adverse pregnancy outcome (APO) in high-risk antiphospholipid syndrome (APS) patients. We have…
Abstract Number: 0128 • ACR Convergence 2025
Defining a Consensus for Critical Data Fields for International Pediatric Antiphospholipid Syndrome Research
Jheel Bhatt¹, Elizabeth Sloan², Selcan Demir³, Mojca Avramovic⁴, Seza Özen⁵, Doruk Erkan⁶ and Tadej Avcin⁷, ¹Advent Health Orlando, Orlando, FL, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³Eskisehir Osmangazi University, Eskişehir, Turkey, ⁴University Children's Hospital, Ljubljana, Slovenia, ⁵Hacettepe University Medical Faculty, Ankara, Turkey, ⁶Hospital for Special Surgery, New York, NY, ⁷University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a rare, thrombo-inflammatory autoimmune disease characterized by thrombosis and nonthrombotic manifestations in patients with persistent positive antiphospholipid antibodies, with…
Abstract Number: 2209 • ACR Convergence 2025
Pregnancy outcomes in Systemic Lupus Erythematosus: Insights from a multicenter Spanish Study on the impact of antiphospholipid antibodies and APS
cristiana Sieiro¹, Jose Ordas Martínez², Ana Merino³, Helena Amar Muñoz⁴, Stefanie Burger⁵, Ignacio Braña Abascal⁵, Carmen Jose Mendéz⁶, Raquel Dos Santos Sobrín⁷, Jose Luis Puga Guzman⁷, Ricardo Blanco⁸ and Víctor Taboada Martínez³, ¹Univrsity of Manchester, Manchester, United Kingdom, ²Complejo Asistencial Universitario de León, León, Spain, ³Hospital Universitario Marqués de Valdecilla, Santader, Spain,, Santander, Spain, ⁴Hospital General Universitario Gregorio Marañón, Rheumatology, Madrid, Spain, Madrid, Spain, ⁵Hospital Universitario Central de Asturias, Rheumatology, Oviedo, Spain, Oviedo, Spain, ⁶Complexo Hospitalario Universitario A Coruña, Rheumatology, A Coruña, Spain, Coruña, Spain, ⁷Hospital Universitario de Santiago de Compostela, Rheumatology, Santiago de Compostela,, Santiago de Compostela, Spain, ⁸Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Pregnancy in patients with systemic lupus erythematosus (SLE) is associated with significant maternal and obstetric risks, particularly in the context of antiphospholipid syndrome (APS).…
Abstract Number: 0144 • ACR Convergence 2025
Duration of Anticoagulation in Antiphospholipid Antibody-positive Patients: Results from an AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Survey
Zeynep Belce Erton¹, Joann Vega², Hannah Cohen³ and Doruk Erkan², ¹Hospital for Special Surgery, Brooklyn, NY, ²hospital for special surgery, New York, NY, ³University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: APS ACTION is a multidisciplinary, international research network focused on developing collaborative studies to improve antiphospholipid syndrome (APS) diagnosis and management. There is limited…
Abstract Number: 0129 • ACR Convergence 2025
Analysis of Antiphosphatidylserine/prothrombin Antibodies as a Predictor of Lupus Anticoagulant in the Pediatric Population
Jonathan Marilao¹, Sean Yates² and Elizabeth Sloan³, ¹University of Texas Southwestern, Dallas, TX, ²University of Texas Southwestern, Dallas, ³UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX
Background/Purpose: Antiphospholipid Syndrome (APS) is a systemic thromboinflammatory autoimmune disease characterized by thrombotic or obstetric events occurring in individuals with persistently positive antiphospholipid antibodies (aPL).…
Abstract Number: 1971 • ACR Convergence 2025
Intracranial Arterial Stenosis in Antiphospholipid Syndrome: A Neglected Vascular Involvement?
Yuying Fan¹, Jinyi Qian¹, Xiaohan Wei², Haoyu Pan¹, Shuyi Yu¹, Zhixia Yang¹, Shiyan Gu¹, Jianzhou Wu¹, Cenyi Wang¹, Tiancheng Zhou¹ and Hui Shi³, ¹Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ²Shanghai JiaoTong University, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombotic events and obstetric complications. While macrovascular and microvascular manifestations have been increasingly acknowledged—particularly…
Abstract Number: 0143 • ACR Convergence 2025
High-dimensional Spectral Flow Cytometry Reveals a Unique Distribution of Circulating B Cells in Patients with Antiphospholipid Syndrome
Yuzhou Gan¹, Srilakshmi Yalavarthi², Yiran Shen¹, Cyrus Sarosh³, Xiangjun Liu⁴, Ajay Tambralli¹, Jacqueline Madison¹, Yu (Ray) Zuo¹ and Jason S. Knight¹, ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, ³University of Michigan, Temperance, MI, ⁴Peking University, Beijing, Beijing, China
Background/Purpose: Background: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by the presence of pathogenic antiphospholipid antibodies (aPL) in the setting of venous or…
Abstract Number: 0127 • ACR Convergence 2025
Single-cell Profiling of Dermal Endothelial Cells Reveals Potential Cell-Cell Interactions in Patients with APS and a History of Cardiac Valve Disease
Wenying Liang¹, Qinmengge Li², Jacqueline Madison¹, Ran Jing¹, Emily Chong¹, Yiran Shen¹, Rachael Bogle³, Srilakshmi Yalavarthi¹, Cyrus Sarosh⁴, Ajay Tambralli¹, Yu (Ray) Zuo¹, Johann Gudjonsson¹, Hui Shi⁵, Pei-Suen Tsou¹, Alex Tsoi³ and Jason S. Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ypsilanti, MI, ³University of Michigan, Holland, OH, ⁴University of Michigan, Temperance, MI, ⁵Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: Some of the rarer manifestations of antiphospholipid syndrome (APS), such as cardiac valve disease, remain poorly understood at the molecular level. A previous study…
Abstract Number: 1721 • ACR Convergence 2025
Excess Mortality in SLE Is Concentrated in Lupus Nephritis and aPL-Positive Subsets: A population-based inception cohort study
Mario Bautista-Vargas¹, Erika Navarro-Mendoza¹, Jaime Flores-Gouyonnet¹, Ali Ardekani¹, Maria Cuellar-Gutierrez¹, Gabriel Figueroa-Parra², Mariana Gonzalez-Treviño³, Jose Antonio Meade-Aguilar⁴, Alain Sanchez-Rodriguez⁵, Andrew C. Hanson¹, Cassondra Hulshizer⁶, Cynthia Crowson⁷ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Boston University/Boston Medical Center, Boston, MA, ⁵ABC Medical Center, Ciudad de México, Federal District, Mexico, ⁶Mayo Clinic, Rochester, ⁷Mayo Clinic, Stewartvillle, MN
Background/Purpose: Five-year survival in SLE has plateaued since the 1990s. Most epidemiologic studies pool all SLE phenotypes; It is possible that the excess mortality observed…
Abstract Number: 0142 • ACR Convergence 2025
Risk Factors for Antiphospholipid Syndrome-associated Nephropathy: A Retrospective Cohort Analysis
Xiaohan Wei¹, Zhixia Yang², Haoyu Pan², Yuying Fan², Jinyi Qian², Shuyi Yu² and Hui Shi³, ¹Shanghai JiaoTong University, Shanghai, China (People's Republic), ²Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To identify independent clinical and laboratory risk factors associated with antiphospholipid syndrome-associated nephropathy (APSN) and highlight the clinical importance of early screening in high-risk…
Abstract Number: 0126 • ACR Convergence 2025
Performance of the 2023 and 2006 APS Classification Criteria in Pediatric Patients Diagnosed with APS: A Multisite Cohort Study
Jacqueline Madison¹, Elizabeth Sloan², Cristina Saez³, Olivia Kwan⁴, Kevin Lewis¹, Jonathan Marilao⁵, Blake Baay⁶, Rasha Elrefai⁴, Marissa Dale⁷, Deborah McCurdy⁸, Jheel Bhatt⁹, Sasidhar Goteti¹⁰, Ekemini Ogbu¹¹, Jason S. Knight¹ and Yu (Ray) Zuo¹, ¹University of Michigan, Ann Arbor, MI, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³Children's Hospital Colorado, Glendale, CO, ⁴Baylor College of Medicine, Houston, TX, ⁵University of Texas Southwestern, Dallas, TX, ⁶Scottish Rite for Children, Dallas, TX, ⁷Hospital for Special Surgery/NYP Cornell, New York, NY, ⁸UCLA Medical Center, Los Angeles, CA, ⁹Advent Health Orlando, Orlando, FL, ¹⁰University of Utah, Salt Lake City, UT, ¹¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Antiphospholipid syndrome (APS) is a thrombo-inflammatory disorder that causes significant morbidity and mortality, even in children. The 2023 ACR/EULAR classification criteria, which use weighted…
Abstract Number: 1497 • ACR Convergence 2025
Acute Care Utilization in Patients with Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus
Megan Barber¹, Fengjuan Yang², Leslie Skeith², Danielle Southern³ and Ann Clarke¹, ¹Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²University of Calgary, Calgary, AB, Canada, ³University of Calgary, Calgary, Canada
Background/Purpose: Little is known about acute care utilization in patients with APS and/or SLE. This study focuses on hospitalizations, intensive care unit (ICU) admissions and…
Abstract Number: 0141 • ACR Convergence 2025
Cytokine profiles in antiphospholipid syndrome
Xiangjun Liu¹, Yuzhou Gan², Chun Li³, Jianping Guo⁴, lei zhu⁵ and yuan jia³, ¹Peking University, Beijing, Beijing, China, ²University of Michigan, Ann Arbor, MI, ³Peking University People's Hospital, Beijing, China (People's Republic), ⁴Peking University People's Hospital, Beijing, Beijing, China, ⁵Affiliated Nantong Rehabilitation Hospital of Nantong University, Nantong, China (People's Republic)
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with unknown etiology. Inflammatory-mediated tissue damage plays an important role in APS. This study aimed to investigate…
Abstract Number: 0125 • ACR Convergence 2025
The IFN Signature is Less Pronounces in Primary Antiphospholipid Syndrome Compared with other Systemic Autoimmune Diseases
Dionysis Nikolopoulos¹, Konstantinos Charitidis², Julius Lindblom², Maria O Borghi³, Guillermo Barturen⁴, Marta Alarcon-Riquelme⁵, Lorenzo Beretta⁶ and Ioannis Parodis⁷, ¹Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³IRCCS, Istituto Auxologico Italiano, Milan, Italy, ⁴Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ⁵Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁶Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, ⁷Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden
Background/Purpose: Primary antiphospholipid syndrome (pAPS) is an autoimmune disease that, unlike many other autoimmune diseases, commonly presents with thrombotic events rather than inflammatory manifestations. A…

1
2
3
…
23
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].